Study Summary
This trial assesses whether a tailored MRI protocol that eliminates one or more aspects of current mpMRI technique is just as effective as the standard mpMRI protocol for cancer detection.
Eligible Conditions
- Prostate Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: through study completion, an average of 1 year
Year 1
The primary objective of this study is to compare the diagnostic accuracy of T2 weighted imaging (T2WI) and restriction spectrum imaging (RSI) (T2WI + RSI) to that of multiparametric MRI (mpMRI), for the detection of individual prostate cancer foci.
Trial Safety
Safety Progress
This is further along than 68% of similar trials
Trial Design
1 Treatment Group
MRI technique
1 of 1
Experimental Treatment
302 Total Participants · 1 Treatment Group
Primary Treatment: restriction spectrum imaging (RSI) · No Placebo Group · Phase 2
MRI technique
Device
Experimental Group · 1 Intervention: restriction spectrum imaging (RSI) · Intervention Types: DeviceTrial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 1 year
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
2,805 Previous Clinical Trials
1,790,077 Total Patients Enrolled
89 Trials studying Prostate Cancer
27,233 Patients Enrolled for Prostate Cancer
Aradhana VenkatesanPrincipal InvestigatorM.D. Anderson Cancer Center
Eligibility Criteria
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:You are anticipated to undergo fusion guided biopsy at MD Anderson.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments